SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Arena Pharmaceuticals, Inc.

Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Arena Pharmaceuticals, Inc. ("Arena" or the "Company") (NASDAQ:ARNA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Pfizer Inc. (NYSE:PFE). Under the terms of the merger agreement, Pfizer will acquire all outstanding shares of Arena common stock in an all-cash transaction. Arena shareholders will receive $100.00 per share in cash for each share of Arena stock they own

The investigation concerns whether the Arena Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Pfizer is paying too little for the Company.

If you own shares of Arena stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/arena-pharmaceuticals-inc-nasdaq-arna/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/677409/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-Arena-Pharmaceuticals-Inc-Nasdaq--ARNA

News Provided by ACCESSWIRE IA via QuoteMedia

The Conversation (0)
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

Agreement supports potential commercial readiness for Bria-IMT using Uneedle's proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell's pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026... Keep Reading...
InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...

Interactive Chart

Latest Press Releases

Related News